Trexquant Investment LP cut its position in Nevro Corp. (NYSE:NVRO) by 48.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,693 shares of the medical equipment provider’s stock after selling 5,415 shares during the period. Trexquant Investment LP’s holdings in Nevro Corp. were worth $424,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Norges Bank bought a new position in Nevro Corp. during the fourth quarter worth about $750,000. Teachers Advisors LLC boosted its position in Nevro Corp. by 11.3% in the fourth quarter. Teachers Advisors LLC now owns 42,735 shares of the medical equipment provider’s stock worth $3,105,000 after buying an additional 4,333 shares in the last quarter. Bank of Montreal Can boosted its position in Nevro Corp. by 79.7% in the first quarter. Bank of Montreal Can now owns 9,653 shares of the medical equipment provider’s stock worth $904,000 after buying an additional 4,281 shares in the last quarter. Columbus Circle Investors boosted its position in Nevro Corp. by 19.2% in the first quarter. Columbus Circle Investors now owns 634,327 shares of the medical equipment provider’s stock worth $59,436,000 after buying an additional 102,341 shares in the last quarter. Finally, First Mercantile Trust Co. boosted its position in Nevro Corp. by 37.3% in the first quarter. First Mercantile Trust Co. now owns 14,049 shares of the medical equipment provider’s stock worth $1,317,000 after buying an additional 3,820 shares in the last quarter.

Shares of Nevro Corp. (NYSE NVRO) opened at 82.34 on Tuesday. The firm’s market cap is $2.42 billion. Nevro Corp. has a 52-week low of $65.82 and a 52-week high of $106.93. The company’s 50-day moving average is $82.51 and its 200 day moving average is $85.22.

Nevro Corp. (NYSE:NVRO) last announced its quarterly earnings data on Monday, August 7th. The medical equipment provider reported ($0.40) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.29) by $0.11. The firm had revenue of $78.02 million for the quarter, compared to analysts’ expectations of $77.75 million. Nevro Corp. had a negative return on equity of 16.25% and a negative net margin of 14.33%. The firm’s quarterly revenue was up 40.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.31) EPS. On average, analysts expect that Nevro Corp. will post ($1.17) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Daily Political and is owned by of Daily Political. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/08/15/nevro-corp-nvro-shares-sold-by-trexquant-investment-lp.html.

A number of research analysts have issued reports on NVRO shares. B. Riley cut shares of Nevro Corp. from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $108.00 to $85.00 in a report on Tuesday, May 9th. Northland Securities reaffirmed a “buy” rating and issued a $96.00 price target on shares of Nevro Corp. in a report on Tuesday, May 9th. Zacks Investment Research cut shares of Nevro Corp. from a “hold” rating to a “sell” rating in a report on Thursday, May 11th. ValuEngine cut shares of Nevro Corp. from a “hold” rating to a “sell” rating in a report on Wednesday, May 24th. Finally, J P Morgan Chase & Co reissued an “overweight” rating and set a $102.00 target price on shares of Nevro Corp. in a report on Monday, July 3rd. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $100.57.

Nevro Corp. Company Profile

Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Want to see what other hedge funds are holding NVRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nevro Corp. (NYSE:NVRO).

Institutional Ownership by Quarter for Nevro Corp. (NYSE:NVRO)

Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with MarketBeat.com's FREE daily email newsletter.